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Abstract
Background: Attention Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioural disorder,
affecting 3–6% of school age children and adolescents in Spain. Methylphenidate (MPH), a mild
stimulant, had long been the only approved medication available for ADHD children in Spain.
Atomoxetine is a non-stimulant alternative in the treatment of ADHD with once-a-day oral dosing.
This study aims to estimate the cost-effectiveness of atomoxetine compared to MPH. In addition,
atomoxetine is compared to 'no medication' for patient populations who are ineligible for MPH (i.e.
having stimulant-failure experience or co-morbidities precluding stimulant medication).
Methods: An economic model with Markov processes was developed to estimate the costs and
benefits of atomoxetine versus either MPH or 'no medication'. The incremental cost per quality-
adjusted life-year (QALY) was calculated for atomoxetine relative to the comparators. The Markov
process incorporated 14 health states, representing a range of outcomes associated with treatment
options. Utility values were obtained from the utility valuation survey of 83 parents of children with
ADHD. The clinical data were based on a thorough review of controlled clinical trials and other
clinical literature, and validated by international experts. Costs and outcomes were estimated using
Monte Carlo simulation over a 1-year duration, with costs estimated from the perspective of the
National Health Service in Spain.
Results: For stimulant-naïve patients without contra-indications to stimulants, the incremental
costs per QALY gained for atomoxetine were € 34 308 (compared to an immediate-release MPH)
and € 24 310 (compared to an extended-release MPH). For those patients who have stimulant-
failure experience or contra-indications to stimulants, the incremental costs per QALY gained of
atomoxetine compared to 'no medication' were € 23 820 and € 23 323, respectively.
Conclusion: The economic evaluation showed that atomoxetine is an effective alternative across
a range of ADHD populations and offers value-for money in the treatment of ADHD.
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Background
Attention Deficit/Hyperactivity Disorder (ADHD) is a
neurobehavioural disorder and one of the most prevalent
chronic health problems affecting school-age children [1],
representing a costly major public health problem [2]. It
begins early in childhood and persists throughout adoles-
cence and well into adulthood in the majority of cases
[3,4]. Affected children commonly exhibit disruptive
behaviour in the classroom, underachieve academically
and tend to have conflictive relations with family mem-
bers and peers [5]. ADHD is also frequently associated
with co-morbidities such as learning disorders, tics, anxi-
ety and conduct disorders [6-8]. Without effective treat-
ments, difficulties associated with the disorder may have
long-term negative consequences such as difficulties in
employment or in forming a good relationship, as well as
the risk of substance abuse, crime and accidental injury [9-
14]. In Spain, the estimated prevalence of ADHD among
school-aged children is around 3–6% [15-17]
Multi-disciplinary approach to the management of ADHD
is often suggested, in which medication may be an inte-
gral part when remedial measures alone prove insufficient
[18]. In Spain, medications licensed for the treatment of
ADHD include methylphenidate hydrochloride (MPH)
and atomoxetine. MPH, which is mainly available as
either immediate-release (IR) or an extended-release (XR)
formulation, has been by far the most widely used medi-
cation for ADHD worldwide. Given that MPH is a stimu-
lant medication however, it may have abuse risk or
produce variations in mood state, sleep disorder or
increase in tic severity [19]. MPH is thus contraindicated
in patients with severe depression, marked anxiety, tics, a
family history or diagnosis of Tourette's syndrome,
known drug dependence or a history of drug dependence
or alcoholism [20]. Treatment guidelines for some of
these contra-indications may have not been followed
strictly in the past due to the lack of alternative medica-
tion options. Atomoxetine, newly introduced in the Span-
ish market, is an alternative to stimulants in the treatment
of ADHD with once-a-day oral dosing [20]. There is con-
sistent evidence that atomoxetine is superior to placebo
while no clear differences have been found between ato-
moxetine and MPH on the grounds of clinical efficacy in
terms of standard measures of ADHD symptom control
[21] though there has been increasing evidence in favour
of MPH [22]. However, atomoxetine may have longer
lasting effects compared to MPH. Results of a placebo-
controlled trial suggests that, among those patients who
respond to atomoxetine, a single dose each morning pro-
vides a lasting effect through to the following morning,
provided that the medication is taken on a regular daily
basis [23]. In contrast, the duration of efficacy of MPH
may be more limited. A single dose of XR-MPH, or three
repeated doses of IR-MPH, would provide about 12 hours
of therapeutic coverage [24-26]. In view of their pharma-
cokinetic and pharmacodynamic characteristics as well as
usual dose regimens, it is as such unlikely that these drugs
would provide therapeutic coverage through the night or
at the time of waking.
The objective of the present study was to estimate the cost-
effectiveness of atomoxetine compared to MPH in the
treatment of children with ADHD. As atomoxetine may
offer a viable alternative for a substantial proportion of
ADHD children who were ineligible for MPH due to a his-
tory of stimulant treatment failure and/or co-morbidities
contra-indicated to simulants, atomoxetine treatment for
these children was also compared to 'no medication' since
they would usually have no alternative medication
options otherwise. The present economic model adapted
the UK model [27] and was modified to compare the costs
and benefits of atomoxetine to that of either MPH or 'no
medication' in the Spanish context.
Methods
Patient population
In recognition that i) children with ADHD are frequently
co-diagnosed with one or more co-morbidities [28] some
of which are contra-indicated for medication with stimu-
lants [29] and ii) a patient's past stimulant history is a
determining factor in clinical outcomes [30,31], patients
in the evaluation are segmented into three mutually exclu-
sive patient groups, according to history of stimulant
treatment failure and contra-indication status.
￿ Stimulant-naïve patients without contra-indications
to stimulants (population 1): These are patients with
no history of pharmacotherapy use and no contra-
indications to stimulants
￿ Stimulant-failed patients without contra-indications
to stimulants (population 2): These are patients who
have previously (prior to entry into the model) been
medicated with MPH but have failed due to lack of
efficacy or intolerable side effects
￿ Stimulant-naïve patients with contra-indications to
stimulants (population 3): These patients have no his-
tory of pharmacotherapy use but are precluded from
using stimulant therapies due to a pre-existing contra-
indicated condition(s) – including severe depression,
marked anxiety, tics, a family history or diagnosis of
Tourette's syndrome, known drug dependence or a
history of drug dependence or alcoholism [29]
Patients who were currently successfully being treated
with MPH were excluded from the analysis because it was
assumed that these patients were unlikely to switch med-
ication.BMC Psychiatry 2009, 9:15 http://www.biomedcentral.com/1471-244X/9/15
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Treatments and comparators
The approach used to calculate the cost-effectiveness of ato-
moxetine is based on current treatment available to each of
the patient groups hence reflecting the likely impact on cost
and outcomes in real practice for each of them.
Atomoxetine was compared to MPH (IR-MPH and XR-MPH
respectively) as a first-line therapy in population 1. Patients
could switch from atomoxetine to MPH and vice versa as a
second-line treatment when the first-line treatment failed.
Subsequently they could stop all therapies upon failure of
second-line therapy and remain on 'no medication' until the
end of the model. For those patient groups (population 2
and 3) who are ineligible for MPH treatment, atomoxetine
was compared to 'no medication'. Patients treated with ato-
moxetine could discontinue the medication upon failure of
therapy and remain un-medicated until the end of the model
while patients in the 'no medication' arm would remain un-
medicated throughout the model.
Model structure
The UK economic model [27] was adapted and re-con-
structed using TreeAge Pro software [32] to calculate and
compare the costs and benefits of atomoxetine to that of
either MPH or 'no medication' in the Spanish context. The
economic evaluation employed a cost-utility analysis to
calculate the incremental cost per quality-adjusted life-
year (QALY) gained by atomoxetine compared with the
treatment options available in Spain.
The model employed a Monte Carlo simulation, whereby a
single patient was followed through the Markov process in
monthly cycles over a period of one year. It was deemed
inappropriate to extend the model beyond the timeframe
covered by the available clinical data. Instead, it was implic-
itly assumed that there are no differences in health benefits
between the medications in the longer term. Costs and out-
comes were accumulated as the patient advanced through
the cycles and 20,000 simulations were performed for each
patient population to establish the mean costs and out-
comes across all possible transitions through the Markov
process. These results were then used to calculate incremen-
tal cost-effectiveness ratios for each comparison in the dif-
ferent patient populations. Given that the model duration
was one year, costs and effects were not discounted. The
Markov process employed a half cycle correction which
meant that patients were attributed their initial health state
utility values half way through the first cycle [33].
The Markov process comprised fourteen and six health
states for population 1 and for population 2 and 3, respec-
tively. Each health state represented one of a range of pos-
sible health outcomes (response and/or occurrence of
adverse events) associated with treatment alternatives
considered in the economic model. Upon entering the
Markov process, patients were distributed into one of four
health states associated with atomoxetine or those associ-
ated with either MPH (in population 1) or 'no medication
(in population 2 and 3). Upon failure of therapy, patients
could move through to health states associated with the
next treatment options (see Figure 1).
Patients could remain within their resident health state
until one of the following events occurred
￿ The patient discontinues medication due to lack of
efficacy: applicable only to patients on an active treat-
ment and in a non-responder health state. The model
assumes a maximum of two consecutive non-response
cycles. A third non-response cycle results in automatic
discontinuation due to lack of efficacy. After discon-
tinuing one medication, the patient will switch imme-
diately to the next alternative in the treatment
algorithm to being the next Markov cycle.
￿ The patient discontinues medication due to a medi-
cation-related adverse event and progresses to the next
line of therapy.
￿ An adverse event resolves
￿ The patient discontinues medication for any other
reason: applicable equally to all patients on active
treatment. These patients are assumed to stop therapy
altogether.
￿ The patient relapses: applicable only to those patients
in a responder health state. A patient who relapses
becomes a non-responder in the following Markov cycle.
Model variables
Costs
Costs were estimated from the perspective of the National
Health Service in Spain. The economic model considered
only the pharmaceutical cost of treatment when compar-
ing medication alternatives, thereby assuming that all
non-drug health care costs and indirect costs were equiva-
lent between the treatment groups being compared.
Such an assumption may be considered biased against the
active therapies which have the potential to reduce symp-
toms and consequently, a patient's reliance on health care
professionals. Furthermore, the cost of drugs associated
with the treatment of medication-related side effects was
not considered. Due to the persistence of insomnia,
patients treated with stimulant (i.e. MPH) are more likely
than patients treated with atomoxetine to require concom-
itant medications for side effects, indicating that the exclu-
sion of these costs may be biased against atomoxetine.
Cost variables used in the Markov process are presented in
Table 1. Most patients with atomoxetine need only a sin-BMC Psychiatry 2009, 9:15 http://www.biomedcentral.com/1471-244X/9/15
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gle capsule per day and a single capsule costs €4.34, irre-
spective of capsule strength. Thus €4.34 was used in the
model as the daily cost of atomoxetine. Calculation of the
daily cost of MPH was based on the estimated average
daily dose taken by patients and the relative use of availa-
ble pack sizes for each medication according to current
market research [34-36]. Unit costs of MPH were derived
from data available at the General Spanish Council of
Pharmacists (CGCOF) [34-36]. Patients in the model
received 30 days of medication per montly cycle.
Health state utility values
Health state utility values for the fourteen possible health
states included in the economic model were based on a
Structure of the Markov process in population 1 Figure 1
Structure of the Markov process in population 1. Abbreviation: ATX = atomoxetine; MPH = methylphenidate; NOTX = 
no medication; R = response; NR = no response; AE = adverse events; NOAE = no adverse events. a Either IR-MPH or XR-
MPH is separately compared to atomoxetine. *Note: The Markov model is similarly structured even when atomoxetine is 
compared to 'no medication' for those who are ineligible for MPH treatment. In this case, all health states related to MPH are 
eliminated from the current model.
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utility valuation survey of 83 parents of children with
ADHD in the UK using standard gamble methodology
[37]. Parents were chosen as the most suitable patient
proxy respondents on the basis that many ADHD children
would be too young to provide reliable responses.
The health state description comprised four domains: 1)
descriptors referring to behaviour during different time peri-
ods throughout the day; 2) information concerning the
child's overall social well-being; 3) attributes regarding med-
ication regimen (e.g. frequency of adminitration); 4) medi-
cation-related adverse events. Descriptions for the four
domains were derived largely based on systematic review of
clinical trials and validated by clinical experts. Further details
of the descriptors for the fourteen health states in terms of
the four domains can be found elsewhere [37].
The health state corresponding to the atomoxetine
'responder without side effects' had the highest utility
value (0.959). Health states corresponding to 'responder
without side effects' for XR-MPH and IR-MPH had utility
values of 0.930 and 0.913, respectively. The higher utility
scores associated with atomoxetine responders are mainly
attributable to its better behavioural profiles. Atomoxet-
ine responder health states reflects improved behaviour in
the early morning as well as at night [23], whereas stimu-
lant responder health states reflects only for a limited time
following administration of medication. For each of the
'no medication' health states, utility values of 0.880 were
obtained from the 'child's own health state' as given by a
subgroup of 23 parents whose children were not currently
receiving medication. Table 2 presents the utiltity scores
incorporated in the economic model.
Transition probabilities
Transition probabilities used to populate the Markov process
and respective data sources are presented in Table 3 and 4.
Note that some are data on file and the details of the sources
can be found in the UK model paper [27]. In addition, clin-
ical trials directly included in this study for the data synthesis
were approved according to local requirements for ethics
and/or regulatory approvals for clinical trials.
Probabilities that did not vary by patient population
(Table 3), including probabilities of medication related
adverse events and discontinuations from treatment, were
derived from placebo-controlled clinical trials for atom-
oxetine [38-42] (some are data on file) and a published
indirect meta-analysis of safety data from randomised pla-
cebo-controlled and active comparator studies of atomox-
etine and methylphenidate [43].
Medication-related adverse events were defined as any
adverse event (i) found to be significant for atomoxetine
in a pooled analysis of safety data from six pivotal ran-
domised placebo-controlled trials [38-40,42] (some are
data on file) (ii) found to be significant for IR-MPH in a
publised quantitative meta-analysis of safety data from
randomised controlled trials [44] or (iii) listed as very
common (frequency ≥ 10%) for IR-MPH and/or XR-MPH
in Summary Product Characteristics [29]. Medication-
related adverse events comprised appetite loss, stomach
ache, vomiting, somnolence, irritability, dizziness,
fatigue, insomnia, headache and nervousness.
Assumptions regarding the persistence of medication-
related adverse events were based on long-term treatment
data for atomoxetine (data on file), where weekly reports
of adverse events, either as a first or repeat occurrence, fell
off with time to fairly constant low levels which, in many
cases, were considered to be close to the baseline report-
ing of such adverse events. These data implied that for
most patients medication-related side effects mainly
occured early on in the treatment and were likely to
resolve within approximately 16 weeks.
Data concerning time to resolution for MPH-related
adverse events were not available. Since adverse events
associated with MPH were mostly considered mild and
transient, the model assumed that, with one exception,
the time to resolution for MPH-related adverse events was
the same as for atomoxetine. The exception to this was
stimulant-associated insomnia, which could persist in a
proportion of cases. The probability that medication-
related insomnia persists in MPH-treated patients was
Table 1: Medication costs in the economic model
Atomoxetine cost IR-MPH cost XR-MPH cost
Average daily dose 1 capsule 43.11a 43.43a
Daily cost of medication € 4.34b € 0.48c € 2.63c
Days on medication per Markov cycle 30 30 30
Cost of medication per Markov cycle 130.20 14.40 78.90
Abbreviations: IR-MPH = immediate-release methylphenidate; XR-MPH = extended-release methylphenidate
a. Market research data [34-36]
b. Daily cost of atomoxetine is independent of average daily dose. Cost is based on a cost per capsule, independent of capsule strength [34-36]
c. Daily costs of IR-MPH and XR-MPH based on current costs applied to the average daily dose, weighted by the relative days of therapy of each 
pack size for each medication [34-36]BMC Psychiatry 2009, 9:15 http://www.biomedcentral.com/1471-244X/9/15
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based on responses collected in a survey of consultant
child and adolesent pscyhiatrists, all highly experienced in
treating children with ADHD (data on file).
Probabilities of response and relapse varied by patient
population (Table 4). The evidence base for these varia-
bles in each of the populations are described below.
Population 1
Probabilities of treatment response in patients with no
history of pharmacotherapy use and no contra-indica-
tions to stimulants were derived from responder rates esti-
mated in a meta-regression analysis [45] of patient-level
data from five randomised active comparator trials of ato-
moxetine and MPH [39,46,47] (some are data on file).
Population 2
Probabilities of response to atomoxetine in patients with
a previous MPH treatment failure but no contra-indica-
tions to stimulants were derived and inferred from
responder rate in the patients treated with atomoxetine
after a failure of an initial 6 weeks treatment with XR-MPH
in a randomised cross-over study of XR-MPH and atomox-
etine [47]. A probability of response on 'no medication' in
this population was derived by applying the relative risk
of response for placebo versus atomoxetine, drawn from
the meta-regression analysis [45].
Population 3
The probability of treatment response in patients with no
history of pharmacotherapy use and contra-indications to
stimulants was derived from responder rate in patients
with no history of pharmacotherapy use in a randomised
placebo-controlled trial of atomoxetine conducted exclu-
sively in an ADHD patient group who had been co-diag-
nosed with tic disorder or Tourette's syndrome [41]. The
limitation of this, of course, is that patients with tics or
Tourette's syndrome constitute a subgroup of, rather than
being representative of, the overall stimulant-contraindi-
cated population. However, in the absence of data from a
more appropriate patient group, this is best estimate avail-
able.
Probabilities of relapse were based on data for stimulant-
naïve and stimulant-exposed patients in a placebo-con-
trolled relapse prevention trial of atomoxetine responders
[48]. In the absence of comparative data, an assumption
of parity was made between relapse rates for all active
Table 2: Utility values derived from the utility valuation survey [37]
Health State N Mean utility value SD 95% CI
Medication with atomoxetine; responder without side effects 83 0.959 0.077 0.942 – 0.976
Medication with atomoxetine; responder with side effects 83 0.937 0.096 0.916 – 0.958
Medication with atomoxetine; non-responder without side effects 83 0.902 0.133 0.873 – 0.931
Medication with atomoxetine; responder with side effects 83 0.886 0.148 0.854 – 0.918
Medication with IR-MPH; responder without side effects 83 0.913 0.128 0.885 – 0.941
Medication with IR-MPH; responder with side effects 83 0.904 0.137 0.875 – 0.933
Medication with IR-MPH; non-responder without side effects 83 0.889 0.154 0.856 – 0.922
Medication with IR-MPH; responder with side effects 83 0.875 0.164 0.840 – 0.910
Medication with XR-MPH; responder without side effects 83 0.930 0.107 0.907 – 0.953
Medication with XR-MPH; responder with side effects 83 0.912 0.124 0.885 – 0.939
Medication with XR-MPH; non-responder without side effects 83 0.898 0.130 0.870 – 0.926
Medication with XR-MPH; responder with side effects 83 0.884 0.143 0.853 – 0.915
No medication; responder 23 0.880 0.133 0.826 – 0.934
No medication; non-responder 23 0.880 0.133 0.826 – 0.934
Abbreviations: IR-MPH = immediate-release methylphenidate; XR-MPH = extended-release methylphenidate; SD = standard deviationBMC Psychiatry 2009, 9:15 http://www.biomedcentral.com/1471-244X/9/15
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Table 3: Transition probabilities used in the Markov process that do not vary by patient population
Probability by treatment
Atomoxetine IR-MPH XR-MPH No medication
Probability of one or more medication-related 
adverse eventsa
0.129 0.129 0.129 0.000
Probability that a medication-related adverse 
event is insomniab
0.000 0.48 0.48 NA
Probability that a medication-related adverse 
event, which is not insomniac
First 4 cycles 0.473 0.473 0.473 NA
Cycles thereafter 1.000 1.000 1.000 NA
Probability that insomnia will persist from one 
Markov cycle to the nextd
First 4 cycles NA 0.953 0.953 NA
Cycles thereafter NA 1.000 1.000 NA
Probability that a non-responder discontinues 
due to lack of efficacy during a Markov cyclee
0.0989 0.0989 0.0989 NA
Probability that a patient discontinue due to a 
medication-related adverse event during a 
Markov cyclef
0.1209 0.1209 0.1209 NA
Probability that a patient discontinues for 
reasons other than lack of efficacy or a 
medication-related adverse event during a 
Markov cyclee
First 4 cycles 0.384 0.384 0.384 NA
Cycles thereafter 0.000 0.000 0.000 NA
Abbreviations: IR-MPH = immediate-release methylphenidate; XR-MPH = extended-release methylphenidate; NA = Not applicable
a. Probabilities based on post hoc analyses of safety data pooled from six randomised placebo-controlled trials of atomoxetine versus placebo [38-
40,42] (some are data on file). Assumption of parity between active treatments based on similar post hoc analyses of data from a limited open-label 
direct comparator study [46], supported by data from a double-blind randomised trial of atomoxetine and XR-MPH (data on file) where the 
proportions of patients experiencing one or more adverse events of any nature were not significantly different between the active treatments. 
Values are net of the placebo rate, meaning that the 'no medication' probability is zero, by definition.
b. The probability based on the relative risk (0.417) of insomnia (atomoxetine vs IR-MPH), estimated in an indirect meta-analysis of safety data [43], 
applied to the risk of insomnia for atomoxetine (4.7%) derived from pooled analysis of safety data from six pivotal randomised placebo-controlled 
trials of atomoxetine [38-40,42] (some are data on file), giving a rate of insomnia for IR-MPH of 4.7/0.417 = 11.27%. The model assumes that 
insomnia is experienced only as a result of taking medication. Therefore, the probability for placebo is not applicable (i.e. zero) and the probabilities 
for active treatments are net of the placebo rate (i.e. subtract 5.1%). As a consequence, the model assumes that patients on atomoxetine have no 
risk of medication-related insomnia. Patients on IR-MPH who experience insomnia will come only from the population who experience one or 
more adverse events as derived in note 1, therefore, for 'if adverse event, probability that insomnia included' = (11.27-5.1)/12.9 = 48%. Parity is 
assumed between IR-MPH and XR-MPH [24,26].
c. Probabilities based on temporal course of treatment-emergent adverse events (data on file) where weekly reports from patients treated with 
atomoxetine over 52 weeks imply that, for most patients, medication-related averse events mainly occur early in the treatment and are likely to 
resolve within approximately 16 weeks. The probability of 0.473 (0.051/4) for the first four cycles with adverse event(s) reflects a nominal 5% of 
patients in whom adverse events (that are not insomnia) persists over this duration of the Markov process. The duration of persistence of adverse 
events (that are not insomnia) is assumed to be similar for each medication.
d. Probabilities based on a survey of six consultant child and adolescent psychiatrists (data on file). Responses suggested that 82.5% of cases of 
stimulant-related insomnia would persist for more than 16 weeks. The model assumes that patients with stimulant-related insomnia that persists 
beyond four cycles will continue to have insomnia as long as they remain on treatment. The probabilities of 0.953 (0.8241/4) for the first four cycles 
of the Markov process and 1.000 for cycles thereafter reflect this.
e. Probabilities based on discontinuation rates, regardless of treatment, from data pooled from seven randomised placebo-controlled trials of 
atomoxetine [38-42] (some are data on file), adjusted for differences between trials with respect to duration of follow-up. Discontinuations due to 
lack of efficacy were assumed to occur in only the non-responder population. In each case, parity is assumed between the active treatments.
f. Probabilities based on discontinuation rates due to adverse events from data pooled from six pivotal randomised placebo-controlled trials of 
atomoxetine [38-40,42] (some are data on file), adjusted for differences between trials with respect to duration of follow-up. Discontinuations due 
to adverse events were assumed to occur only in the population experiencing one or more medication-related adverse events and therefore were 
net of the placebo rate. In each case, parity is assumed between the active treatments.BMC Psychiatry 2009, 9:15 http://www.biomedcentral.com/1471-244X/9/15
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treatments and also between patients who were contrain-
dicated for stimulants and those who were not.
For all transition probability variables, where applicable,
the assumption of parity between IR-MPH and XR-MPH
was made based on data published from head-to-head tri-
als of treatments [24,26].
Sensivity analysis
Extensive sensivity analyses were carried out on cost, util-
ity and transition probability variables.
Results
The results of the economic model are summarised in
Table 5. Overall, treatment with atomoxetine was associ-
Table 5: Total costs, QALYs and incremental cost-effectiveness estimated in the economic model by patient population
Population Cost per patient QALYs per patient Incremental cost per 
QALY gained
ATX arm Comparator arm ATX arm Comparator arm
Population 1a 
(comparator: IR-MPH)
€ 1 047 € 366 0.930 0.910 € 34 308
Population 1a 
(comparator: XR-MPH)
€ 1 208 € 902 0.933 0.920 € 24 310
Population 2b 
(comparator: 'no medi-
cation')
€ 919 € 0 0.919 0.880 € 23 820
Population 3c 
(comparator: 'no medi-
cation')
€ 969 € 0 0.922 0.880 € 23 323
Abbreviations: ATX = atomoxetine; IR-MPH = immediate-release methylphenidate; XR-MPH = extended-release methylphenidate; QALY = Quality-
adjusted life year
a. Stimulant-naïve patients without contra-indications to stimulants
b. Stimulant-failed patients without contra-indications to stimulants
c. Stimulant-naïve patients with contra-indications to stimulants
Table 4: Transition probabilities used in the Markov process that vary by patient population
Probability by treatment
Population Atomoxetine IR-MPH XR-MPH No medication
Probability of response to 
treatment
1. Stimulant-naïve, not contra-
indicateda
0.7051 0.7727 0.7727 NA
2. Stimulant-failed, not contra-
indicatedb
0.6346 NA NA 0.3731
3. Stimulant-naïve, contra-
indicatedc
0.6667 NA NA 0.423
Probability of relapse per 30-
day periodd
1. Stimulant-naïve, non contra-
indicated
0.0206 0.0206 0.0206 NA
2. Stimulant-failed, non contra-
indicated
0.0257 NA NA 0.0447
3. Stimulant-naïve, contra-
indicated
0.0206 NA NA 0.0387
Abbreviations: IR-MPH = immediate-release methylphenidate; XR-MPH = extended-release methylphenidate; NA = not applicable
a. Probabilities of response in stimulant-naïve patients are not contra-indicated are based on a meta-regression analysis [45] of response data from 
randomised active comparator trials of atomoxetine and MPH [39,46,47] (some are data on file). Assumption of parity between stimulants is based 
on head-to-head trials of IR-MPH and XR-MPH [24,26].
b. Probabilities of response in MPH-exposed (failed) patients in whom stimulants are not contra-indicated are derived and inferred from responder 
rates in a crossover trial of atomoxetine and XR-MPH [47]. A probability of response for 'no medication' is derived by applying the relative risk of 
repsonse for placebo versus atomxetine, drawn from the meta-regression analysis [45].
c. Probabilities of response in stimulant-naïve patients in whom stimulants are contra-indicated are based on responder rates from a randomised 
placebo-controlled trial of atomoxetine in patients with tics or Tourette's syndrome [41].
d. Probability of relapse = 1 - [(1-C)(1/E)], where C = the proportion of patients relapsing and E = approximate total number of follow-up days, 
derived from a relapse prevention study [48], divided by the approximate number of days per Markov cycle. Parity is assumed between active 
medications.BMC Psychiatry 2009, 9:15 http://www.biomedcentral.com/1471-244X/9/15
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ated with higher costs and better health outcomes, trans-
lated into increased QALYs, when compared to either
MPH (both IR-MPH and XR-MPH) or 'no medication'.
For the stimulant-naïve patients without contra-indica-
tions to stimulants (population 1), treatment with atom-
oxetine was associated with additional costs of € 681
compared to IR-MPH and € 306 compared to XR-MPH.
For the patients having stimulant-failure experience or
contra-indications to stimulants (population 2 and 3),
atomoxetine was in principle the only alternative option
available. Atomoxetine was thus compared to 'no medica-
tion' within these groups of patients. The additional cost
of atomoxetine treatment compared to 'no medication'
was € 919 in the stimulant-failed patients without contra-
indications to stimulants (population 2). Similar cost (€
969) was incurred as well by atomoxetine treatment in the
stimulant-naïve patients but having contra-indications to
stimulants (population 3).
Patients who started treatment with atomoxetine experi-
enced slightly less time with adverse events than patients
with MPH in population 1, while the duration of response
over the 1-year period was similar between the two groups
(results not shown). This, together with the higher utility
value associated with a response to atomoxetine relative
to the MPH or 'no medication', translated into QALY
gains for patients treated with atomoxetine. For the stim-
ulant-naïve patients without contra-indications to stimu-
lants (population 1), treatment with atomoxetine was
associated with 0.020 and 0.013 additional QALYs
gained, when compared to IR-MPH and XR-MPH, respec-
tively. The magnitude of additional QALYs gained associ-
ated with atomoxetine, was greater among the patients
having stimulant-failure experience or contra-indications
to stimulants (population 2 and 3) as 'no medication' (i.e.
comparator of atomoxetine in these patient populations)
was associated with the lowest utility values of 0.880. The
additional QALYs gained associated with atomoxetine
treatment was 0.039 and 0.042 in population 2 and 3,
respectively.
The incremental cost per QALY gained associated with
atomoxetine was consistently lower among the patients
having stimulant-failure experience or contra-indications
to stimulants (population 2 and 3), in comparison to that
of the stimulant naïve patients without contra-indications
to stimulant (population 1). The incremental cost per
QALY gained of atomoxetine was € 23 820 and € 23 323
in population 2 and 3 respectively while it was € 34 308
and € 24 310 compared to IR-MPH and XR-MPH respec-
tively in population 1. This is an intuitive result because
atomoxetine is the most cost-effective in the patient group
in which there are no pharmacotherapy alternatives cur-
rently available (i.e. in population 2 and 3) and least cost-
effective in the treatment naïve patient group for which
other pharmacotherapy options are available (i.e. popula-
tion 1).
In addition, an extensive range of one-way and scenario-
based sensitivity analyses were performed for other uncer-
tain model variables and assumptions. In general, the
incremental cost per QALY gained in each population was
insensitive to changes in key clinical and cost variables
(results not shown; the full results of sensitivity analyses
are available from the authors upon request). However,
the sensitivity analyses show that the utility values of all
health states are crucial determinants of the cost-effective-
ness of atomoxetine.
Given the importance of the utility values to the results of
the economic model, additional sensitivity analyses of the
utility values were explored for the stimulant-naïve
patients without contra-indications to stimulants (popu-
lation 1), in which both atomoxetine and MPH were pos-
sible treatment options. The additional analysis was to see
how the results of the model are affected when differences
between utility values of corresponding health states of
atomoxetine and those of MPH (either IR-MPH or XR-
MPH) are reduced or eliminated.
The incremental cost per QALY gained associated with
atomoxetine was € 34 308 (compared to IR-MPH) and €
24 310 (compared to XR-MPH) for the base case analysis.
When differences in the utility values between corre-
sponding health states of different treatments were
reduced by 25% by increasing the base case utility values
of MPH, the incremental cost per QALY gained became €
48 643 and € 30 685 (see Figure 2). It again increased to
€ 68 101 and € 43 835 when differences in utility values
were reduced by 50%. Finally, when differences in utility
values are eliminated (i.e. 100% reduction), the incre-
mental cost per QALY ratios went up dramatically.
This sensitivity analysis shows that when differences in
utility values between treatment groups are removed the
incremental cost per QALY gained of atomoxetine rises to
unacceptable levels. However, the modest increase in the
cost per QALY when differences are reduced by up to 50%
and the sound methodology used to derived the utility
values [32] serves to minimise the uncertainty surround-
ing the utility values and thus maximise the reliability of
the base case model results.
Discussion
This study sought to apply pharmacoeconomic modelling
techniques to the process of informing the selection of a cost
effective treatment for children with ADHD in Spain. Atom-
oxetine, a newly introduced treatment option in the Spanish
market, was compared to methylphenidate, which had beenBMC Psychiatry 2009, 9:15 http://www.biomedcentral.com/1471-244X/9/15
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the only approved medication available for ADHD children
in Spain. In addition, atomoxetine was compared to 'no
medication' among those who were ineligible for methyl-
phenidate treatment (i.e. patients having a history of stimu-
lant-treatment failure or co-morbidities contra-indicated to
stimulants). The results of the economic model showed that
atomoxetine is associated with better outcomes in terms of
QALYs over a 1-year time horizon, compared to methylphe-
nidate (both IR-MPH and XR-MPH) as well as 'no medica-
tion'. Although response rate was found to be equal or
higher for methylphenidate, patients responding to atomox-
etine appeared to experience a more stable and longer-last-
ing response (throughout a night till the following early
morning) [23] than those patients responding to methyl-
phenidate. In addition, parents of the ADHD children
tended to prefer nonstimulants to stimulants when the rest is
the same otherwise. The nature of such response with atom-
oxetine and parent preferences for nonstimulants, which
were reflected in the utility value survey conducted by Secnik
and colleagues [37], led to higher utility values associated
with atomoxetine treatment and thereby a greater number of
QALYs overall in the context of the economic evaluation.
Overall, the incremental costs per QALYs gained of atom-
oxetine were between € 23 323 and € 34 308, depending
on the patient population. The incremental costs per
QALYs gained were consistently lower when atomoxetine
was compared to 'no medication', although 'no medica-
tion' option was associated with 'zero costs'. This clearly
shows that introducing atomoxetine in Spain is beneficial
at least for those who are ineligible for methylphenidate
treatment as they do not have any treatment alternatives
otherwise. Even when compared with methylphenidate
(in particular, XR-MPH), atomoxetine as first line therapy
was found to be a cost-effective strategy in the treatment
of ADHD in Spain [49].
The clinical inputs to the economic model were primarily
based on head-to-head randomised clinical trial evidence.
Sensitivity analyses confirmed that base case results were
likely to be insensitive to changes in input parameters,
with the exception of utility values. The utility values
appeared to be a key component in determining the cost-
effectiveness of atomoxetine. However, these utility values
were obtained from a robust utility valuation study of
ADHD health states [37] that involved parents of children
with ADHD as the respondent population and employed
standard gamble methodology. In order to minimise any
uncertainty or bias surrounding the utility values, the
health states descriptors used in the study interviews were
The ICERs of atomoxetine under varying utility values used in the model in population 1 Figure 2
The ICERs of atomoxetine under varying utility values used in the model in population 1. Abbreviations: IR-MPH = 
immediate-release methylphenidate; XR-MPH = extended-release methylphenidate; QALY = Quality of life years.
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derived largely based on data from randomised clinical
trials and validated by clinical experts [37]. Nevertheless,
caution is required when interpreting these utility values
since there is no large trial to confirm and validate the
health states descriptors. Furthermore, there have been
concerns over the use of utilities (and therefore QALYs)
for the paediatric population [50]. While ADHD children
tend to underestimate their 'disease-specific problems',
the validity of utilities elicited with parent proxies has not
been fully understood yet [28]. The validation of these
utility values is necessary when data become available
from sufficiently powered randomised controlled trials.
Several limitations of this study are worth noting. Firstly,
our study only considered the drug treatments of ADHD.
However, behavioural treatment represents 'a therapeutic
mainstay in most European countries' [22,51]. In the
recent cost-effectiveness analysis based on the MTA data
[52], behavioural treatment was found to be more cost
effective than intensive medication management (mainly
stimulants) in ADHD children with co-morbid conditions
whereas the opposite was true in pure ADHD children
(i.e. no co-morbid conditions). The study then suggested
behavioural treatment with or without medication as the
most cost-effective choice for co-morbid ADHD popula-
tion. While behavioural treatment is certainly of value,
further research to examine the cost-effectiveness of
ADHD treatments including nonstimulant atomoxetine
remains worthwhile and valuable since stimulants are
often contra-indicated for co-morbid conditions. Sec-
ondly, patient group involved in the utility survey were
those living in the UK and thus their response may differ
from those living in Spain. However, as there were no
available utility values of treatments for ADHD children
in Spain, those utility values used here were the best avail-
able data. Thirdly, the perspective of this analysis was that
of the National Health Service in Spain and thus only
direct medical costs were considered in the model. The
exclusion of indirect costs however may be biased against
active treatments as effective treatments are likely to
decrease these costs. Therefore the estimates of cost-effec-
tiveness of atomoxetine compared to 'no medication'
option can be considered conservative. Fourthly, it could
be argued that a longer timeframe may be desirable to
take into account longer-term differences in costs and
adverse effects of treatments. However, any omissions due
to the shorter timeframe are likely to be again conservative
in that they bias the model generally against the active
therapies and more specifically against atomoxetine. For
example, the model does not allow for the pattern of care
of ADHD patients to change according to response to
active therapy. This means the omission of non-drug costs
within the model are assumed to be the same across all
disease health states. Finally, in an ideal situation it would
be preferable to have utility scores estimated from the
patient perspective. However, the use of parents of ADHD
children as patient proxies is seen to provide the best prac-
tical alternative.
Conclusion
In general, the results of this study showed atomoxetine to
be within the bounds of reasonable cost-effectiveness for
Spain. In comparison with methylphenidate, atomoxet-
ine as first line therapy appeared as a cost-effective strat-
egy. The additional value offered by atomoxetine was
even clearer for those who have no alternative treatment
options otherwise. The results of this analysis are consid-
ered to be robust, having been based on the best available
clinical evidence, expert opinion and a rigorously con-
ducted utility valuation study of ADHD-related health
states.
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